Clinical Trial Results: Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating onapristone plus anastrozole for refractory hormone receptor positive endometrial cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Onapristone (onapristone)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-07-17